Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer ...
Dermata Therapeutics, Inc. (DRMA) is a small, clinical-stage biotechnology and dermatology company headquartered in San Diego, California. Founded in 2014, it is led by Gerald T. Proehl, who serves as Founder/Chairman/President/CEO. The company’s overarching purpose is to discover, develop, and commercialize dermatologic solutions that target medical and cosmetic skin ailments. ...Dermata Therapeutics, Inc. (DRMA) is a small, clinical-stage biotechnology and dermatology company headquartered in San Diego, California. Founded in 2014, it is led by Gerald T. Proehl, who serves as Founder/Chairman/President/CEO. The company’s overarching purpose is to discover, develop, and commercialize dermatologic solutions that target medical and cosmetic skin ailments.
From a business perspective, Dermata has historically operated like a drug-development organization, running clinical trials to validate efficacy and safety for its lead molecules. The provided company description highlights DMT310 as its principal experimental drug: it has completed Phase IIb clinical trials for moderate-to-severe acne, finished a Phase Ib proof-of-concept study for mild-to-moderate psoriasis, and is undergoing Phase 2 evaluation for moderate-to-severe rosacea. In parallel, Dermata has been progressing DMT410, which has completed Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic-related concerns.
In recent investor-facing materials referenced in the provided snippets, Dermata has communicated a strategic pivot away from purely pharmaceutical development toward a broader focus on developing and distributing scientifically backed dermatologic solutions (including reference to a skincare brand/“Tome” and a planned launch mid-2026). This shift suggests the company intends to leverage its dermatology science and clinical learning while potentially changing commercialization pathways, product packaging, and go-to-market strategies.
Operationally, Dermata is very lean, with an indicated full-time employee count around 9 people (company size 2–10 employees in the provided context), which typically implies reliance on contractors, partnerships, and targeted external clinical/manufacturing resources rather than a large in-house organization.
From a financial and cost viewpoint, as a clinical-stage company, its major expense categories typically include R&D, clinical trial execution, regulatory work, and associated overhead. The provided market/financial snapshot indicates a small market capitalization (sub-$2B) and negative return metrics consistent with early-stage development economics (e.g., negative returns on assets/equity and negative free cash flow measures). Exact cost structure (BOM/manufacturing bill of materials, product-level COGS) and detailed financial statements are not provided in the supplied data, so they cannot be stated reliably.
Key people beyond the CEO are not specified in the provided inputs, though the CEO’s long tenure in the industry is noted in the snippets (including prior leadership at Santarus). Strategically, the company’s stated “wishes” or near-term objectives, based on the provided references, center on advancing its dermatology programs and executing commercialization plans, including an initial product launch expected in mid-2026 with additional innovations to follow.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-7.6M
+38.5%
-60.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-7.8M
+30.5%
-2.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.79x
+167.6%
-60.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
